Abstract
A 26-year-old male developed narcoleptic-like episodes while on pegylated interferon-alpha 2b (peg-IFN-α2b) therapy for stage IIIB melanoma. Once peg-IFN-α2b was discontinued, the narcoleptic-like episodes eradicated. A case report and review of the literature are presented in this article.
Keywords:
Pegylated IFN-α2b; loss of consciousness; melanoma; narcolepsy; syncope.
Copyright© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
MeSH terms
-
Adult
-
DNA Mutational Analysis
-
HLA Antigens / genetics
-
Humans
-
Interferon alpha-2
-
Interferon-alpha / adverse effects*
-
Interferon-alpha / therapeutic use*
-
Magnetic Resonance Imaging
-
Male
-
Melanoma / drug therapy*
-
Narcolepsy / complications*
-
Polyethylene Glycols / adverse effects*
-
Polyethylene Glycols / therapeutic use*
-
Recombinant Proteins / adverse effects
-
Recombinant Proteins / therapeutic use
-
Skin Neoplasms / drug therapy*
-
Syncope
Substances
-
HLA Antigens
-
Interferon alpha-2
-
Interferon-alpha
-
Recombinant Proteins
-
Polyethylene Glycols
-
peginterferon alfa-2b